氨氯地平、瑞舒伐他汀联合非诺贝特治疗高血压合并冠心病的临床研究

目的 探讨氨氯地平、瑞舒伐他汀联合非诺贝特治疗高血压合并冠心病的临床疗效.方法 选择我院内科于2014年3月至2016年3月期间收治的98例高血压合并冠心病的患者为研究对象,根据随机数表法分为观察组和对照组,每组49例,对照组予氨氯地平及瑞舒伐他汀治疗,观察组在此基础上联合应用非诺贝特治疗,疗程3个月.比较两组患者治疗前后的血压、血脂及颈动脉内膜中层厚度(IMT)的变化.结果 治疗后,两组患者的收缩压、舒张压均较治疗前显著降低(P<0.05),但是组间比较差异均无统计学意义(P>0.05);观察组患者的甘油三酯(TG)、胆固醇(TC)、低密度蛋白-胆固醇(LDL-C)及颈动脉IMT分别为(1.84±0.57)mmol/L、(3.98±0.92)mmol/L、(2.25±0.68)mmol/L和(0.78±0.08)mm,均明显低于对照组的(2.21±0.79)mmol/L、(4.46±1.01)mmol/L、(3.19±0.79)mmol/L和(0.84±0.08)mm,高密度脂蛋白-胆固醇(HDL-C)为(1.39±0.21)mmol/L,明显高于对照组的(1.25±0.20)mmol/L,差异均有统计学意义(P<0.05).结论 氨氯地平、瑞舒伐他汀联合非诺贝特治疗高血压合并冠心病不仅可以降低患者血压,还可以有效调节血脂,延缓动脉粥样硬化进展.

Clinical study of amlodipine,rosuvastatin combined with fenofibrate in the treatment of hypertension with coronary heart disease

Objective To evaluate the therapeutic effect of amlodipine, rosuvastatin combined with fenofibrate in the treatment of hypertension with coronary heart disease. Methods A total of 98 cases of hypertension with coro-nary heart disease, who admitted to Department of Internal Medicine of our hospital from March 2014 to March 2016, were selected and divided into the observation group and the control group according to random number table method, with 49 cases in each group. The control group was treated with amlodipine, rosuvastatin and atorvastatin therapy, and the observation group was treated by additional fenofibrate based on the treatment of the control group. All patients were treated for 3 months. The changes of blood pressure, blood lipid and carotid intima-media thickness (IMT) were compared between the two groups before and after treatment. Results After the treatment, the systolic and diastolic blood pressure of the two groups were significantly lower than those before the treatment (P<0.05), but there were no significant differences between the two groups (P>0.05). After the treatment, triglyceride (TG), cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and carotid artery IMT in the observation group were (1.84 ± 0.57) mmol/L, (3.98±0.92) mmol/L, (2.25±0.68) mmol/L and (0.78±0.08) mm, respectively, which were significantly lower than (2.21± 0.79) mmol/L, (4.46±1.01) mmol/L, (3.19±0.79) mmol/L and (0.84±0.08) mm in the control group. High density lipopro-tein cholesterol (HDL-C) in the observation group was (1.39±0.21) mmol/L, which was significantly higher than (1.25± 0.20) mmol/L in the control group (P<0.05). Conclusion In the treatment of hypertension with coronary heart disease, amlodipine, rosuvastatin combined with fenofibrate can not only reduce the blood pressure, but also effectively regulate blood lipids, and delay the progression of atherosclerosis.